Latest FoRx Therapeutics News & Updates

See the latest news and media coverage for FoRx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
FoRx Therapeutics (FoRx)

Clinical-stage biotechnology company developing targeted cancer therapeutics

forxtherapeutics.com
Headquarters
Basel, Switzerland
Founded year
2019
Company type
Private company
Number of employees
34–50

Last updated

Latest news about FoRx Therapeutics (FoRx)

In short: FoRx disclosed FORX-428’s structure and said Phase 1 readouts were expected by the end of 2026.

Company announcements

FoRx

FoRx Therapeutics closes USD 50M Series A financing

Existing investors including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participate. The funds advance Phase 1 development of PARG inhibitor FORX-428, with initial data expected mid-2026.

FoRx

FoRx Therapeutics doses first patient with FORX-428

The open-label Phase 1 study in advanced solid tumors starts in the U.S., with initial data expected by mid-2026.

Unlock all announcements with a

Media coverage

Yahoo Finance

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response

Basel, Switzerland - August 11, 2025 - FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the dosing of the first patient...

Unlock all articles with a

Never miss news about FoRx

Track FoRx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.